Cargando…

MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma

BACKGROUND: This study aimed to better understand the prognostic effect of multiple genetic markers and identify more subpopulations at ultra high risk of poor outcome in bone marrow (BM) metastatic neuroblastoma (NB). METHODS: We screened the MYCN, 1p36 and 11q23 loss of heterozygosity (LOH) status...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yue, Zhi‐Xia, Xing, Tian‐Yu, Zhao, Wen, Zhao, Qian, Wang, Xi‐Si, Su, Yan, Gao, Chao, Liu, Shu‐Guang, Ma, Xiao‐Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9041068/ https://www.ncbi.nlm.nih.gov/pubmed/35137546 http://dx.doi.org/10.1002/cam4.4583

Ejemplares similares

Impact of 11q Loss of Heterozygosity Status on the Response of High-Risk Neuroblastoma With MYCN Amplification to Neoadjuvant Chemotherapy
por: Lu, Xian-Ying, et al.
Publicado: (2022)

Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification
por: Yue, Zhi-Xia, et al.
Publicado: (2019)

MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma
por: Yue, Zhi-Xia, et al.
Publicado: (2017)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020)

MYCN Amplifications and Metabolic Rewiring in Neuroblastoma
por: Pouliou, Marialena, et al.
Publicado: (2023)

Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain
por: He, Shuning, et al.
Publicado: (2016)

MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Zeineldin, Maged, et al.
Publicado: (2020)

Genetic Instability and Intratumoral Heterogeneity in Neuroblastoma with MYCN Amplification Plus 11q Deletion
por: Villamón, Eva, et al.
Publicado: (2013)

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)

Genetic variation associated with childhood and adult stature and risk of MYCN‐amplified neuroblastoma
por: Semmes, Eleanor C., et al.
Publicado: (2020)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma
por: Lau, Diana T., et al.
Publicado: (2015)

Effects of preoperative chemotherapy on neuroblastoma with MYCN amplification: a surgeon’s perspective
por: Chui, Chanhon
Publicado: (2020)

CCNB1IP1 prevents ubiquitination‐mediated destabilization of MYCN and potentiates tumourigenesis of MYCN‐amplificated neuroblastoma
por: Zhou, Yang, et al.
Publicado: (2023)

Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology
por: Minard, V, et al.
Publicado: (2000)

Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma
por: Keller, Kaylee M., et al.
Publicado: (2022)

Extracellular Vesicle-Based Method for Detecting MYCN Amplification Status of Pediatric Neuroblastoma
por: Panachan, Jirawan, et al.
Publicado: (2022)

MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis
por: Bleeker, Gitta, et al.
Publicado: (2014)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

MYCN and Metabolic Reprogramming in Neuroblastoma
por: Bansal, Mohit, et al.
Publicado: (2022)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma
por: Seier, Johanna A, et al.
Publicado: (2021)

Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma
por: Yagyu, Shigeki, et al.
Publicado: (2016)

SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma
por: Tan, Kezhe, et al.
Publicado: (2022)

Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification
por: Schleiermacher, G, et al.
Publicado: (2007)

Clinical Characteristics and Outcome of Patients with Neuroblastoma Presenting Genomic Amplification of Loci Other than MYCN
por: Guimier, Anne, et al.
Publicado: (2014)

MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET Database
por: Zhang, Peng, et al.
Publicado: (2017)

Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples
por: Somasundaram, Dinesh Babu, et al.
Publicado: (2019)

CT-Based Radiomics Signature With Machine Learning Predicts MYCN Amplification in Pediatric Abdominal Neuroblastoma
por: Chen, Xin, et al.
Publicado: (2021)

Ferroptosis vulnerability in MYCN‐driven neuroblastomas
por: Dasgupta, Shayani, et al.
Publicado: (2022)

Identification of a Five-Gene Signature Derived From MYCN Amplification and Establishment of a Nomogram for Predicting the Prognosis of Neuroblastoma
por: Xia, Yuren, et al.
Publicado: (2021)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening
por: Iehara, T, et al.
Publicado: (2006)

Binomial Mitotic Segregation of MYCN-Carrying Double Minutes in Neuroblastoma Illustrates the Role of Randomness in Oncogene Amplification
por: Lundberg, Gisela, et al.
Publicado: (2008)

cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma
por: Chen, Qing-Rong, et al.
Publicado: (2004)

CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma
por: Zhong, Zhi-Yong, et al.
Publicado: (2018)

Differential Clinical Significance of Neurotrophin-3 Expression according to MYCN Amplification and TrkC Expression in Neuroblastoma
por: Seo, Eunseop, et al.
Publicado: (2019)

Hypoxia-Dependent Expression of TG2 Isoforms in Neuroblastoma Cells as Consequence of Different MYCN Amplification Status
por: Currò, Monica, et al.
Publicado: (2020)

Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by MYCN Amplification
por: Berthold, Frank, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ulhmp6bkkm8do2g48tnmort2hk